Interference of daratumumab with compatibility testing in blood bank
Plasma cell myeloma accounts for 1% of malignant tumors and 10%–15% of hematopoietic neoplasms. Daratumumab (DARA), a novel targeted immunotherapy drug, was approved by the Food and Drug Administration to treat relapsed/refractory multiple myeloma. DARA, which is a CD38-targeted immunomodulatory dru...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Global Journal of Transfusion Medicine |
| Subjects: | |
| Online Access: | http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2019;volume=4;issue=2;spage=240;epage=242;aulast= |